Taken together, these results highlight the potential for anti-VEGFR-2 antibodies to relieve innate immune suppression induced by VEGF, providing new insights into the mechanisms by which combined VEGFR-2 and PD-L1 antibody therapy leads to enhanced anti-tumor efficacy. Here, VEGFA is linked to neoplasm.